Journal metric profile

Diabetes Technology & Therapeutics Impact Factor 2025

Diabetes Technology & Therapeutics has a 2025 Journal Impact Factor of 6.3 and is listed in Q1 with a JCR category rank of 24/191.

JCR-based Impact Factor 6.3 2025 metric year
5-Year Impact Factor 5.9 Longer citation window
JCR Quartile Q1 Subject-category quartile
JCR Category Rank 24/191 Recorded category rank

Diabetes Technology & Therapeutics impact factor and ranking

This profile summarizes the journal metrics and publication information available in the current directory record.

Page reviewed August 6, 2026

Diabetes Technology & Therapeutics metric snapshot

Diabetes Technology & Therapeutics has a bibliometric profile in this directory for 2025. The publisher recorded for the journal is MARY ANN LIEBERT, INC. Its listed Clarivate Journal Citation Reports (JCR)-based Journal Impact Factor is 6.3. The five-year Journal Impact Factor is 5.9, giving a second citation window for comparison. The journal is recorded in quartile Q1 for its listed JCR category.

Category position and quartile

The recorded JCR category position is 24 out of 191 journals. Based on that rank position, the journal sits within approximately the top 13% of the listed category. Its listed quartile is Q1. Category ranks and quartiles are field-specific and are not measures of the quality of an individual article.

How the citation indicators compare

The five-year Journal Impact Factor (5.9) is 0.4 points lower than the standard Journal Impact Factor (6.3). Without journal self-citations, the Impact Factor is 5.2, a difference of 1.1 points from the listed standard value. The Journal Citation Indicator (JCI) is recorded as 1.57. These measures use different definitions or citation windows, so they are most useful when read together rather than treated as interchangeable scores.

Citation and publication counts

For 2025, the directory record for Diabetes Technology & Therapeutics lists total cites: 7,456; total articles: 129; citable items: 138. These fields describe different parts of the JCR record and should not be combined into an article-level quality score.

Citation half-life profile

The cited half-life is 5.5 years, indicating the median age of items that contributed citations to the journal in the reporting framework. The citing half-life is 4.4 years, indicating the median age of references used by the journal’s articles.

Identifiers and verification

Diabetes Technology & Therapeutics is identified in this directory by print ISSN 1520-9156 and electronic ISSN 1557-8593. The publisher is recorded as MARY ANN LIEBERT, INC. When making submission, library, or research-evaluation decisions, verify the title and identifiers against the journal publisher and the official Clarivate Journal Citation Reports record.

Complete journal information

Use this table to verify the individual metric values, identifiers and publication details stored for this journal.

Journal nameDiabetes Technology & Therapeutics
Abbreviated journalDIABETES TECHNOL THE
PublisherMARY ANN LIEBERT, INC
Metric year2025
Overall rank1,333
ISSN1520-9156
eISSN1557-8593
Total cites7,456
Total articles129
Citable items138
Cited half-life5.5 years
Citing half-life4.4 years
JCR-based Journal Impact Factor6.3
5-Year Impact Factor5.9
Impact Factor without journal self-cites5.2
Journal Citation Indicator1.57
JCR Impact Factor quartileQ1
JCR category rank24/191
Database record updated

Frequently asked questions

What is the 2025 JCR-based Journal Impact Factor of Diabetes Technology & Therapeutics?

The Journal Impact Factor recorded in this directory as a Clarivate Journal Citation Reports (JCR)-based value for Diabetes Technology & Therapeutics is 6.3 for the 2025 metric year.

What are the JCR quartile and category rank of Diabetes Technology & Therapeutics?

Diabetes Technology & Therapeutics is listed with quartile Q1 and category rank 24/191. These values are category-specific and should be verified against the official JCR record when used for formal assessment.

What is the five-year Journal Impact Factor of Diabetes Technology & Therapeutics?

The five-year Journal Impact Factor recorded for Diabetes Technology & Therapeutics is 5.9. It uses a longer citation window than the standard Journal Impact Factor.

Who publishes Diabetes Technology & Therapeutics?

Diabetes Technology & Therapeutics is listed in this directory as being published by MARY ANN LIEBERT, INC.

Journals in the same approved specialty or subject are shown first, followed by same-publisher or similar-metric records when needed.

Research Area

Subject: Medicine
Specialty: Endocrinology & Metabolism

Subject assignments on this website are used for navigation and are separate from official Journal Citation Reports categories.